Savannah Pettey

Ms. Savannah Pettey

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
KSKarly Stanley
Karly Stanley
MFMiKaela Field
MiKaela Field
APAdriene M. Pavek
Adriene M. Pavek
AMA. Paulina Medellin
A. Paulina Medellin
SPSavannah Pettey
Savannah Pettey
SHSheri Holmen
Sheri Holmen
Background/Objectives: Despite several FDA-approved therapies, metastatic melanoma remains a major clinical challenge, particularly in patients with brain metastases, which are associated with treatment failure and melanoma-related mortality. The molecular mechanisms underlying the development of melanoma brain metastasis remain incompletely understood. Methods: Building on our prior discovery that AKT1 activates focal adhesion kinase (FAK), we analyzed clinical-genomic data to evaluate the association between PTK2 mRNA expression and overall survival in melanoma cohorts. For functional assessment, we used complementary in vitro and in vivo approaches to investigate the effects of FAK overexpression, FAK activation, FAK kinase-dependence, and expression of FAK-related non-kinase (FRNK) on cell proliferation, migration, and invasion. Complementary syngeneic and genetically engineered mouse models were used to assess tumor growth and metastatic dissemination. Results: High PTK2 (FAK) mRNA expression was associated with shorter overall survival in melanoma cohorts, including patients with BRAF-mutant melanoma treated with BRAF and MEK inhibitors. Pharmacologic MEK inhibition increased FAK phosphorylation at the activating Y397 site, suggesting a potential compensatory response to MAPK pathway inhibition. Functional studies implicated FAK expression and signaling in melanoma cell migration, invasion, tumor growth, and metastatic dissemination. Expression of a kinase dead FAK mutant markedly impaired tumor growth and metastasis in vivo. Conclusions: These findings implicate FAK signaling in melanoma progression and metastatic dissemination. The observed effects of FAK mutants support the further investigation of FAK kinase activity as a therapeutic target. In addition, increased FAK Y397 phosphorylation following MEK inhibition provides a rationale for evaluating combined FAK and MAPK pathway inhibition clinically in patients with advanced melanoma.